Apatinib in Combination With Ifosfamide and Etoposide (IE) for Relapsed or Refractory Osteosarcoma Progressed Upon First-line Chemotherapy (AIEO): a Prospective, Multiple-centre, Single-arm, Phase 2 Trial
Latest Information Update: 18 May 2024
At a glance
- Drugs Etoposide (Primary) ; Ifosfamide (Primary) ; Rivoceranib (Primary)
- Indications Osteosarcoma
- Focus Therapeutic Use
- Acronyms AIEO
Most Recent Events
- 11 May 2024 Planned End Date changed from 1 Apr 2024 to 1 Apr 2026.
- 11 May 2024 Planned primary completion date changed from 1 Apr 2023 to 1 Apr 2026.
- 11 May 2024 Status changed from recruiting to suspended for trying another trial with randomized design.